Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients
ICI therapy has greatly improved patient outcomes in melanoma, but at the cost of immune-related adverse events (irAEs). Data on the chronicity of irAEs, especially in real-world settings, are currently limited. We performed a retrospective chart review of 161 adult patients with melanoma treated wi...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Jezik: | English |
| Izdano: |
MDPI AG
2022-10-01
|
| Serija: | Current Oncology |
| Teme: | |
| Online dostop: | https://www.mdpi.com/1718-7729/29/10/629 |